Effect of Nicotinamide Riboside on Airway Inflammation in COPD: A Randomized, Placebo-Controlled Trial

In this randomized, double-blind, placebo-controlled clinical trial, scientists treated patients with stable COPD with the NAD+ precursor nicotinamide riboside for 6 weeks and followed-up 12 weeks later.